Interpretation variability of 18FDG-positron emission tomography studies in dementia.
OBJECTIVE
Functional imaging studies such as 18F-fluoro-18-labeled-deoxyglucose-positron emission tomography (18FDG-PET) are being used increasingly in the evaluation of patients with dementia. The authors evaluate inter- and intraobserver interpretation agreement in a diverse group of patients with clinically diagnosed dementia and subjective memory complaints, as well as two healthy control subjects.


METHODS
Ninety-six patients with clinical diagnoses of probable Alzheimer's disease (n = 18), possible Alzheimer's disease (n = 33), dementia (n = 26), and mild memory impairment (n = 17), as well as two healthy control subjects were studied using 18FDG-PET. Three observers graded all studies for regional 18FDG uptake in the temporal, parietal, and frontal regions bilaterally. The studies also were interpreted for the presence of bilateral temporoparietal hypometabolism, which typically is present in Alzheimer's disease. The kappa statistic was used to determine intra- and interobserver agreement for regional 18FDG uptake and bilateral temporoparietal hypometabolism.


RESULTS
There was excellent intraobserver (kappa = .56, P < 0.0005) and interobserver (kappa = .51, P < 0.0005) interpretation agreement for bilateral temporoparietal hypometabolism. There also was excellent intraobserver (kappa = .61, P < 0.000) and interobserver (kappa = .55, P < 0.000) interpretation agreement of regional 18FDG uptake. Interobserver agreement was extremely high in those patients who were considered clinically to have possible (kappa = .42, P < 0.001) or probable (kappa = .42, P < 0.01) Alzheimer's disease.


CONCLUSIONS
Results confirm that bilateral temporoparietal hypometabolism is the metabolic abnormality associated with the diagnosis of probable Alzheimer's disease. Furthermore, intra- and interobserver agreement of visual interpretation of 18FDG-PET images indicates that 18FDG-PET is acceptable as an imaging technique in the clinical evaluation of the dementia patient.
Hoffman
J M
JM
Section of Nuclear Medicine, Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Durham, North Carolina, USA.
Hanson
M W
MW
Welsh
K A
KA
Earl
N
N
Paine
S
S
Delong
D
D
Coleman
R E
RE
D000328:Adult; D000368:Aged; D003704:Dementia / Q000000981:diagnostic imaging*; D003847:Deoxyglucose / Q000031:analogs & derivatives*; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D015588:Observer Variation; D014055:Tomography, Emission-Computed
D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D003847:Deoxyglucose